T. Peros Golubicic (Zagreb, Croatia), G. Casoni (Forli, Italy), R. Borie (Paris, France), M. Kreuter (Heidelberg, Germany)
LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis
R. Yao, Y. Cao, Y. R. He, Z. Zeng, Z. A. Liang (Chengdu, China)
|   |
Chronic tachypnoe of infancy - diagnostic assessment with and without biopsy
D. Rauch, S. K. Braun, M. Johanna, M. Wetzke, N. Schwerk, S. Reu, F. Brasch, M. Griese (Munich, Hannover, Bielefeld, Germany)
| |
Angiopoietin-2 gene polymorphism as prognostic factor in caucasians with idiopathic pulmonary fibrosis
S. Ohshimo, Y. Horimasu, F. Bonella, H. Iwamoto, N. Ishikawa, K. Fujitaka, Y. Haruta, H. Murai, N. Hattori, N. Hirohashi, K. Tanigawa, J. Guzman, U. Costabel, N. Kohno (Hiroshima, Japan; Essen, Bochum, Germany)
| |
Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone
M. Korfei, S. Skwarna, I. Henneke, O. Klymenko, G. Dahlem, S. Ziegler, D. von der Beck, W. Klepetko, L. Fink, W. Seeger, O. Krämer, A. Guenther (Giessen, Mainz, Greifenstein, Germany; Vienna, Austria)
| |
Diffuse dendriform pulmonary ossification in a usual interstitial pneumonia-like distribution: A distinct entity or a variant of idiopathic pulmonary fibrosis?
H. Slabbynck, T. De Beukelaar, F. Hoet, D. De Surgeloose, K. Charels, J. Van Goethem (Antwerpen, Belgium)
| |
From HRCT to morphology in diffuse parenchymal lung diseases(DPLDs)
A. Benova, N. Stoeva, A. Penev, T. Minchev, G. Kirova, P. Dakova, D. Lekova (Sofia, Bulgaria)
| |
Health-related quality of life in idiopathic pulmonary fibrosis (IPF): First results based on the European IPF registry
M. Wacker, S. Witt, P. Bonniaud, B. Crestani, C. Vancheri, A. Wells, F. Drakopanagiotakis, A. Günther, R. Leidl (Dijon, Paris, France; Neuherberg, Giessen, Munich, Germany; Catania, Italy; London, United Kingdom)
| |
Impulse oscillometry measurements are correlated to quality of life in patients with pulmonary sarcoidosis
K. Karagiannis, A. Bikov, M. Bonifazi, H. Kalsi, H. Lota, S. Meah, P. Barnes, A. U. Wells, P. Paredi, O. S. Usmani, E. Renzoni (London, United Kingdom)
| |
Decreased circulatory receptor for advanced glycation end-products is associated with poorer survival in patients with idiopathic pulmonary fibrosis
H. Iwamoto, Y. Horimasu, T. Nakashima, S. Ohshimo, N. Ishikawa, K. Fujitaka, Y. Haruta, H. Murai, N. Hattori, W. Mazur, N. Kohno (Hiroshima, Japan; Helsinki, Finland)
| |
Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis
M. Kato, F. Takahashi, S. Yagishita, T. Asao, R. Kanemaru, K. Suina, H. Bascoro, F. Nurwidya, I. Kobayashi, K. Muraki, T. Sato, N. Shimada, M. Takahashi, K. Takahashi (Tokyo, Japan)
| |
Seasonal variation of serum KL-6 levels in patients with interstitial lung diseases
H. Ohnishi, S. Miyamoto, S. Kawase, T. Kubota, A. Yokoyama (Nankoku, Japan)
| |
Prognostic factors analysis of patients with rapid progressive interstitial pneumonias treated by direct hemoperfusion with polymyxin B-immobilized fiber column
K. Oishi, K. Aoe, T. Utsunomiya, Y. Murata, K. Sakamoto, T. Ohfuji, Y. Ogata, T. Matsumoto, H. Ueoka, Y. Mimura (Ube, Japan)
| |
Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis
K. Hostettler, E. Papakonstantinou, J. Zhong, G. Karakiulakis, D. Lardinois, M. Tamm, M. Roth (Basel, Switzerland; Thessaloniki, Greece)
| |
The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE)
V. Cottin, D. Hansell, K. Antoniou, A. Nair, M. Atwood, N. Sverzellati, G. Oster, D. Weycker, H. R. Collard, A. Wells (Lyon, France; London, United Kingdom; Heraklion, Greece; Boston, San Francisco, United States Of America; Parma, Italy)
| |
The enhancement of Stanniocalcin-1 (STC1) secretion increases the ability of mesenchymal stem cells (MSCs) to reduce bleomycin-induced lung fibrosis in a mouse model through inhibition of endoplasmic reticulum stress (ER-stress)/TGFbeta1 pathway
S. Ohkouchi, M. Ono, M. Ichinose (Sendai, Japan)
| |
Low density lipoprotein receptor-related protein 1 is a novel activator of beta1 Integrin-dependent fibroblast adhesion, spreading and migration
L. Wujak, Y. Chen, K. T. Preissner, M. Wygrecka (Giessen, Germany)
| |
Screening potential biomarkers for idiopathic pulmonary fibrosis in bronchoalveolar lavage fluid
I. M. Vercauteren, S. E. Verleden, B. M. Vanaudenaerde, E. Vandermeulen, D. Ruttens, H. Bellon, E. De Dycker, C. Dooms, J. Yserbyt, G. M. Verleden, W. A. Wuyts (Leuven, Belgium)
| |
Quantitative CT scanning using a lung emphysema software package in familial Birt-Hogg-Dubé syndrome
S. Samuel, D. Yates, J. Lee, K. Tucker, E. Silverstone (Sydney, Australia)
| |
Management of spontaneous pneumothorax in patients with or without Birt-Hogg-Dubé syndrome
P. C. Johannesma, M. Jonker, T. van der Wel, J. van Waesberghe, J. van Moorselaar, F. Menko, P. Postmus (Amsterdam, Netherlands)
| |